

# **The metabolic demands of cancer cells are coupled to their size and protein synthesis rates**

Sonia C. Dolfi<sup>1</sup>, Leo Li-Ying Chan<sup>2</sup>, Jean Qiu<sup>2</sup>, Philip M. Tedeschi<sup>1</sup>, Joseph R. Bertino<sup>1</sup>, Kim M. Hirshfield<sup>1</sup>, Zoltán N. Oltvai<sup>3</sup>, Alexei Vazquez<sup>4,5,\*</sup>

<sup>1</sup>Department of Medicine, <sup>4</sup>Department of Radiation Oncology and <sup>5</sup>Center for Systems Biology, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, USA

<sup>2</sup>Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA, USA

<sup>3</sup>Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

## **Outline**

- 2 Maximum likelihood estimate of the protein synthesis rate**
- 3 Average amino acid molecular weight in the expressed proteome**
- 4 Statistical test for volume dependence**
- 5 Personalized metabolic models**
- 12 Supplementary Figures**
- 16 Supplementary Tables**

## Maximum likelihood estimate of the protein synthesis rate

The experimentally measured import rates of an essential amino acid are assumed to be proportional to the protein synthesis rate:  $f_a = S_a f_P + \Delta f_a$ , where  $S_a$  is the relative content of amino acid  $a$  in proteome (Table S1),  $f_P$  is the rate of protein synthesis and  $\Delta f_a$  represents the variability introduced by the experimental procedures. We further assume that the experimental noise  $\Delta f_a$  follows a normal distribution with an amino acid dependent variance  $\sigma_a$ . Under these assumptions the probability to observe the reported exchange rates for essential amino acids is

$$(Eq. 1) \quad P(f | f_P, \sigma) = \prod_{a=1}^n \frac{1}{\sqrt{2\pi\sigma_a^2}} \exp\left(-\frac{(f_a - S_a f_P)^2}{2\sigma_a^2}\right)$$

where the product is restricted to essential amino acids and  $n$  is the number of essential amino acids. Maximizing (Eq. 1) with respect to  $f_P$  and  $\sigma_a$  we obtain their maximum likelihood estimates (MLE)

$$(Eq. 2) \quad f_P = \frac{\sum_{a=1}^n \frac{S_a f_a}{\sigma_a^2}}{\sum_{a=1}^n \frac{S_a^2}{\sigma_a^2}}$$

$$(Eq. 3) \quad \sigma_a^2 = \frac{1}{n} \sum_{a=1}^n (f_a - S_a f_P)^2$$

We solve these equations recursively, starting from the assumption that the measurements of all amino acids exchanges have the same variance

$$(Eq. 4) \quad \sigma_a(0) = \sigma$$

$$(Eq. 5) \quad f_P(0) = \frac{\sum_{a=1}^n S_a f_a}{\sum_{a=1}^n S_a^2}$$

Then, recursively, we compute first  $\sigma_a(t)$  using as input  $f_P(t-1)$  and then  $f_P(t)$  using as input  $\sigma_a(t)$ . We continue this procedure until the relative error:  $\varepsilon = \text{abs}(f_P(t) - f_P(t-1)) / f_P(t)$  is smaller than  $10^{-6}$ .

The MLE estimates for  $f_P$  and  $\sigma_a$  are reported in Tables S5 and S6, respectively.

## Average amino acid molecular weight in the expressed proteome

The average amino acid molecular weight in the expressed proteome was calculated as

$$w_{aa} = \sum_a S_a W_a$$

where  $S_a$  is the abundance of amino acid  $a$  in the expressed proteome and  $W_a$  is its molecular weight, as reported in Refs. [9, 21].

## Statistical test for volume dependence

Given a test quantity  $Y_i$  (protein content, DNA content or protein synthesis rate) measured across  $i=1, \dots, n$  cell lines with cell volumes  $V_i$ , we assume that  $Y_i = \mu V_i^\alpha + \sigma V_i^\beta X_i$ , where  $\mu$  and  $\sigma$  are model parameters and  $\alpha=\beta=0$  for the I model,  $\alpha=1$  and  $\beta=0$  for the VDM model, and  $\alpha=\beta=1$  for the VDMV model, and  $X_i$  are independent random variables with a standard normal distribution. The likelihood to observe the data  $Y_i$  given these models is

$$P(Y | \mu, \sigma) = \prod_{i=1}^n \frac{1}{\sqrt{2\pi\sigma^2 V_i^\beta}} \exp\left(-\frac{(Y_i - \mu V_i^\alpha)^2}{2\sigma^2 V_i^\beta}\right)$$

For each model, we assign to  $\mu$  and  $\sigma$  their maximum log-likelihood  $L = \ln P(Y | \mu, \sigma)$ , obtaining

$$\mu_{MLE} = \frac{\sum_{i=1}^n Y_i V_i^{\alpha-\beta}}{\sum_{i=1}^n V_i^{2\alpha-\beta}}$$

$$\sigma_{MLE}^2 = \frac{1}{n} \sum_{i=1}^n \frac{(Y_i - \mu_{MLE} V_i^\alpha)^2}{V_i^\beta}$$

The validity of each model is then quantified applying a Shapiro-Wilk normality test to

$$X_i = \frac{Y_i - \mu_{MLE} V_i^\alpha}{\sigma_{MLE} V_i^{\beta/2}}$$

A model is rejected if the resulting statistical significance falls below 0.05.

## Personalized metabolic models

As starting point, we utilize a genome-scale metabolic reconstruction of a generic human cell [1] that includes most biochemical reactions catalyzed by enzymes encoded in the human genome. We add auxiliary reactions to represent nutrient uptake, excretion of metabolic byproducts, basal ATP demand needed for cell maintenance, basal rate of protein degradation, and synthesis of cell biomass components (proteins, lipids, RNA and DNA) (Vazquez et al [2], Table S1). We assume that the cell is in a steady state where the production and consumption of every metabolite and macromolecules balances, known as the flux balance constraint [1]. We use  $S_{mi}$  to denote the stoichiometric coefficient of metabolite  $m$  in reaction  $i$ . We use  $F_i$  to denote the net steady state reaction rate (flux) of the  $i^{\text{th}}$  reaction per cell, where all reversible reactions are represented by a forward and backward rate, respectively. Reactions are divided into nutrient import reactions ( $I$ ), reactions taking place in the cytosol ( $C$ ) and reactions taking place in the mitochondria ( $M$ ). We use  $\phi_c$  to denote the relative cell volume fraction occupied by the  $c^{\text{th}}$  cellular compartment. In particular, we denote by  $N_0$  the non-metabolic protein content per cell and by  $\phi_0$  its occupied volume fraction. We assume the proliferation rate ( $\mu$ ) and the relative volume fraction occupied by macromolecules and organelles ( $\phi_{max}$ ) are known and are given as input parameters of the model. Finally, we estimate the metabolic fluxes and compartment densities as the solution of the following optimization problem:

Find the  $F_i$  and  $\phi_c$  that maximize the total content of non-metabolic protein

$$(1) \quad N_0$$

subject to the metabolic constraints: flux balance constraints

$$(2) \quad \sum_i S_{mi} F_i = 0$$

minimum/maximum flux constraints

$$(3) \quad v_{i,\min} \leq F_i \leq v_{i,\max}$$

minimum/maximum volume fraction constraints

$$(4) \quad 0 \leq \phi_c \leq \phi_{\max}$$

molecular crowding constraints

$$\begin{aligned}
(5) \quad & \sum_{i \in C} a_i F_i \leq \phi_C V \\
& \sum_{i \in M} a_i F_i \leq \phi_M V \\
& a_{M,ATP} \sum_{i \in M | S_{ATP,i} > 0} S_{ATP,i} F_i \leq \phi_M V \\
& \phi_0 + \phi_C + \phi_M \leq \phi_{\max}
\end{aligned}$$

where  $V$  is the cell volume,  $c_i$  is the nutrient import cost associated with the uptake reaction  $i$ ,  $a_i = v_i / k_{eff,i}$  are the crowding coefficients of metabolic enzymes (enzyme molar volume / enzyme effective turnover)[3], and  $a_{M,ATP} = v_{s,M} / r_M$  the crowding coefficient of mitochondria ATP generation (ATP synthesis rate per mitochondria mass / mitochondria specific volume) [4, 5]. As a difference with our previous work [2], here we express the metabolic fluxes  $F_i$  in units of mol/cell/hour. We can recover our previous equations recalling that the metabolic flux per cell volume is given by  $f_i = F_i / V$ .

### *Personalized models*

The model is tailored for each cell line by specifying the proliferation rate  $\mu$ , the cell volume  $V$ , the DNA content and the reported exchange fluxes. The model reaction fluxes representing exchange fluxes are fixed to the experimentally measure values, by setting  $v_{i,min} = v_{i,max} = F_{i,reported}$ .

### *Proliferation rate*

The doubling time  $t_D$  of each cell line in the NCI60 panel was obtained from the Developmental Therapeutics Program at the NCI ([http://dtp.nci.nih.gov/docs/misc/common\\_files/cell\\_list.html](http://dtp.nci.nih.gov/docs/misc/common_files/cell_list.html)). Proliferation rates were computed as  $\mu = \ln(2) / t_D$ .

### *Nuclear DNA content*

The nuclear DNA content of each cell line in the NCI60 panel was estimated using the reported karyotypes for these cell lines [6] and the chromosome lengths reported by Ensembl. Specifically, using the reported copy number for each chromosome band we calculated an average karyotype for each chromosome. Multiplying the average chromosome karyotype by the chromosome length in base pairs and summing over all chromosomes we obtained the DNA content in base pairs (nucleotides/cell). The latter was converted to mol/cell after dividing by the Avogadro number.

The nuclear DNA content of a normal cell was calculated similarly, using as input the normal chromosomes copy number.

### *Mitochondrial DNA*

The mitochondrial DNA (mtDNA) was assumed proportional to the mitochondrial volume, with a density of 0.3 fmol of mtDNA/pL. The density was calculated based on the reported mitochondrial DNA ( $\sim 0.75 \mu\text{g}/10^6$  cells) and protein ( $\sim 2.5 \text{ mg}/10^6$  cells) content in chick embryo fibroblasts (Table III in Ref. [7]). Dividing the mtDNA mass per cell by the average DNA molecular weight ( $\sim 331 \text{ g/mol}$ ) we obtain a density of 2.3 fmol mtDNA/cell, and dividing by the mitochondrial protein content a density of  $0.92 \mu\text{mol mtDNA/g}$  of mitochondrial protein. Multiplying the latter number by the specific volume of mitochondria ( $2.6 \text{ mL/g protein}$  [8]), we obtain a density of 0.3 fmol mtDNA/pL of mitochondria.

### *RNA*

The RNA composition was estimated by their relative abundance per cell dry weight [9]. The abundance per cell dry weight were converted to abundance per cell volume after dividing by the typical cell specific volume  $4.3 \text{ mL/g}$  [10]. The abundance per cell volume was finally converted to abundance per cell by multiplying by our measurements of cell volume for each of the cell lines on the NCI60 panel.

### *Lipids*

The lipids composition was estimated by their relative abundance per cell dry weight [9]. The abundance per cell dry weight were converted to abundance per cell volume after dividing by the typical cell specific volume  $4.3 \text{ mL/g}$  [10]. The abundance per cell volume was finally converted to abundance per cell by multiplying by our measurements of cell volume for each of the cell lines on the NCI60 panel.

### *Protein content*

Proteins are divided into cytosolic and mitochondrial proteins. Within the cytosol, proteins were divided into three pools: ribosomal-, components of metabolic enzyme complexes-, and non-metabolic proteins. Each ribosome contributes to  $n_{PR}=82$  proteins/ribosome (49 in the 60S and 33 in the 40S subunits [11]). The ribosome related protein concentration was computed as  $P_{CR}=n_{PR}f_{CP}/k_R$ , where  $f_{CP}$  is the cytosolic protein synthesis rate and  $k_R$  the protein synthesis rate per ribosome. Each enzyme contributes with  $n_{PE}=2.4$  proteins in average, estimated as median enzyme molecular weight ( $98,750 \text{ g/mol}$ , reported above) divided by the median molecular weight of a human protein ( $40,835 \text{ g/mol}$ ). The median molecular weight of a human protein was estimated from the median protein length (355 amino acids [12]) and the typical amino acid composition [9]. The enzyme related cytosolic protein concentration was computed as  $P_{CE}=\sum_i n_{PE}f_i/k_i$ . A similar subdivision is carried on for mitochondrial

proteins.

### *Kinetic parameters*

The effective turnover numbers,  $k_{eff,i}$ , quantify the reaction rate per enzyme molecule. For example, for an irreversible single substrate reaction satisfying Michaelis-Menten kinetics,  $k_{eff}=kS/(K+S)$ , where  $k$  is the enzyme turnover number,  $K$  the half-saturation concentration and  $S$  the substrate concentration. The turnover numbers of some human enzymes are reported in the BRENDA database [13]. They have a typical value of  $10 \text{ sec}^{-1}$  and a significant variation from  $1$  to  $100 \text{ sec}^{-1}$  (Vazquez et al [2], Table S2). However, for most reactions we do not know the turnover number, the kinetic model, or the metabolite concentrations, impeding us to estimate  $k_{eff}$ . To cope with this indeterminacy we performed a sampling strategy, whereby the  $k_{eff,i}$  were sampled from a reasonable range of values, and then focused on median and the 90% confidence intervals (see Sensitivity analysis below).

### *Crowding coefficients*

Dividing the mitochondrion specific volume (3.15 mL/g in mammalian liver [14] and 2.6 mL/g in muscle [8]) by the rate of ATP production per mitochondrial mass (0.1-1.0 mmol ATP/min/g [15-17]) we obtain  $a_M$  values between 0.0026 to 0.032 min/mM. Except when specified, we use the median 0.017 min/mM. Dividing the ribosome molar volume ( $v_R = 4,000 \text{ nm}^3 \times 6.02 \cdot 10^{23}/\text{mol}=2.4 \text{ L}/\text{mmol}$ ) by the rate of protein synthesis per ribosome (0.67 proteins/min [18]) we obtain  $a_R=3.6 \text{ min}/\text{mM}$ . The enzyme crowding coefficients were estimated as  $a_i=v_E/k_i$ . Multiplying the median molecular weight of human enzymes (98,750 g/mol, Vazquez et al [2], Table S2) by the enzymes specific volume (approximated by the specific volume of spherical proteins, 0.79 mL/g [19]) we obtain an estimated enzymes molar volume of  $v_E=0.078 \text{ L}/\text{mmol}$ .

### *Maximum macromolecular density*

The maximum macromolecular density cannot exceed 100% of the cell volume, therefore  $\phi_{max}=1$ . We have previously used the upper bound of 0.4 based on the typical macromolecular density of cells. However, there may be some variability among cancer cell lines. Furthermore, the constraint over the exchange fluxes of essential amino acids determines the protein content, which is the major component of the cell biomass.

### *Protein synthesis*

The flux balance equation for proteins synthesized in the cytosol is formulated as follows. We account for three major categories, proteins not associated with metabolism, proteins that are components of



enzyme complexes and that are encoded in nuclear genes, and the cytosol ribosomal proteins, with their concentrations (moles/cell volume) denoted by  $P_0$ ,  $P_{NE}$ , and  $P_{CR}$ , respectively. In proliferating cells, these concentrations will decrease at a rate  $(\mu+k_D)(P_0+P_{NE}+P_{CR})$ , where  $\mu$  represents the contribution to cell growth and  $k_D=0.01/\text{h}$  [20] is the basal protein turnover rate. Putting all these elements together, the balance between protein turnover and synthesis implies  $f_{CP}-k_D[P_0+ n_{PE}\sum_i(f_i/k_{eff,i}) + n_{PR}f_{CP}/k_R]=0$ , where the index  $i$  runs over all enzyme catalyzed reactions excluding ATP synthase, NADH dehydrogenase, complex III, and complex IV. In a similar manner we formulated the flux balance equation for mitochondrial proteins encoded in the mitochondrial DNA. The mitochondrial protein synthesis reaction accounted for the synthesis of ATP synthase, NADH dehydrogenase, complex III, complex IV and the mitochondria ribosomes.

### *DNA synthesis*

We explicitly considered a nuclear and a mitochondrial DNA synthesis reaction, each matching the DNA synthesis demands of their respective compartment upon cell proliferation.

### *Flux bounds*

All reversible reactions were represented by an irreversible reaction on each direction with their own effective turnover number  $k_{eff,i}$ . Flux bounds were set to  $v_{i,min}=0$  and  $v_{i,max}=\infty$ , except for reported exchange fluxes ( $v_{i,min}=v_{i,max}=F_{i,reported}$ ) and for the auxiliary reactions representing the basal rate of protein turn over ( $v_{i,min}=v_{i,max}=k_D$ ) and the biomass production reaction ( $v_{i,min}=v_{i,max}=\mu$ ).

### *Simulations*

The optimization problem in equations (1)-(5) was solved in Matlab, using the linear programming function `linprog`.

### *Sensitivity analysis*

The turnover numbers of human enzymes  $k$  have significant variations from 1 to 100  $\text{sec}^{-1}$  and the distribution of  $\log_{10}(k)$  is approximately uniform in this range (Vazquez et al [2], Table S2). Based on this data we sampled the  $\log_{10}(k_{eff})$  values from a uniform distribution in the range between  $\log_{10}(1)$  to  $\log_{10}(100)$ . For each specified condition we run 100 simulations. On each simulation, for each reaction, a value of  $k_{eff,i}$  is extracted from the distribution described above. With this set of  $k_{eff,i}$  parameters we then solve the optimization problem (1)-(5) and obtain estimates for the reaction rates. Based on the 100 simulations we finally estimate the median and 90% confident intervals for the rate of each reaction. 100 simulations were proven to be sufficient to capture the overall range of behavior, since


running 1,000 simulations did not result in a significant change in the median and 90% confidence intervals.

## References

1. Mo ML, Jamshidi N, Palsson BO: **A genome-scale, constraint-based approach to systems biology of human metabolism.** *Mol Biosyst* 2007, **3**(9):598-603.
2. Vazquez A, Markert EK, Oltvai ZN: **Serine biosynthesis with one carbon catabolism and the glycine cleavage system represents a novel pathway for ATP generation.** *Plos One* 2011, **6**(11):e25881.
3. Vazquez A, de Menezes MA, Barabasi AL, Oltvai ZN: **Impact of limited solvent capacity on metabolic rate, enzyme activities, and metabolite concentrations of *S. cerevisiae* glycolysis.** *PLoS Comput Biol* 2008, **4**(10):e1000195.
4. Vazquez A, Liu J, Zhou Y, Oltvai ZN: **Catabolic efficiency of aerobic glycolysis: The Warburg effect revisited.** *BMC Syst Biol* 2010, **4**:58.
5. Vazquez A, Oltvai ZN: **Molecular crowding defines a common origin for the warburg effect in proliferating cells and the lactate threshold in muscle physiology.** *Plos One* 2011, **6**(4):e19538.
6. Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, Scudiero DA, Weinstein JN, Kirsch IR: **Karyotypic complexity of the NCI-60 drug-screening panel.** *Cancer Res* 2003, **63**(24):8634-8647.
7. D'Agostino MA, Nass MM: **Specific changes in the synthesis of mitochondrial DNA in chick embryo fibroblasts transformed by Rous sarcoma viruses.** *J Cell Biol* 1976, **71**(3):781-794.
8. Schwerzmann K, Hoppeler H, Kayar SR, Weibel ER: **Oxidative capacity of muscle and mitochondria: correlation of physiological, biochemical, and morphometric characteristics.** *Proc Natl Acad Sci U S A* 1989, **86**(5):1583-1587.
9. Sheikh K, Forster J, Nielsen LK: **Modeling hybridoma cell metabolism using a generic genome-scale metabolic model of *Mus musculus*.** *Biotechnol Prog* 2005, **21**(1):112-121.
10. Frame KK, Hu WS: **Cell volume measurement as an estimation of mammalian cell biomass.** *Biotechnol Bioeng* 1990, **36**(2):191-197.
11. Alberts B: **Molecular biology of the cell**, 5th edition. edn. New York, N.Y.,: Garland Science; 2008.
12. Brocchieri L, Karlin S: **Protein length in eukaryotic and prokaryotic proteomes.** *Nucleic Acids Res* 2005, **33**(10):3390-3400.
13. Schomburg I, Chang A, Schomburg D: **BRENDA, enzyme data and metabolic information.** *Nucleic Acids Res* 2002, **30**(1):47-49.
14. Glas U, Bahr GF: **Quantitative study of mitochondria in rat liver. Dry mass, wet mass, volume, and concentration of solids.** *J Cell Biol* 1966, **29**(3):507-523.
15. Wibom R, Hultman E, Johansson M, Matherei K, Constantin-Teodosiu D, Schantz PG: **Adaptation of mitochondrial ATP production in human skeletal muscle to endurance training and detraining.** *J Appl Physiol* 1992, **73**(5):2004-2010.
16. Short KR, Nygren J, Barazzoni R, Levine J, Nair KS: **T(3) increases mitochondrial ATP production in oxidative muscle despite increased expression of UCP2 and -3.** *Am J Physiol Endocrinol Metab* 2001, **280**(5):E761-769.
17. Hou XY, Green S, Askew CD, Barker G, Green A, Walker PJ: **Skeletal muscle mitochondrial ATP production rate and walking performance in peripheral arterial disease.** *Clin Physiol*


- Funct Imaging* 2002, **22**(3):226-232.
18. Princiotta MF, Finzi D, Qian SB, Gibbs J, Schuchmann S, Buttgerit F, Bennink JR, Yewdell JW: **Quantitating protein synthesis, degradation, and endogenous antigen processing.** *Immunity* 2003, **18**(3):343-354.
  19. Lee B: **Calculation of volume fluctuation for globular protein models.** *Proc Natl Acad Sci U S A* 1983, **80**(2):622-626.
  20. Savinell JM, Palsson BO: **Network analysis of intermediary metabolism using linear optimization. I. Development of mathematical formalism.** *J Theor Biol* 1992, **154**(4):421-454.
  21. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, Srivas R, Palsson BO: **Global reconstruction of the human metabolic network based on genomic and bibliomic data.** *Proc Natl Acad Sci U S A* 2007, **104**(6):1777-1782.
  22. Holbeck SL, Collins JM, Doroshow JH: **Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.** *Mol Cancer Ther* 2010, **9**(5):1451-1460.

## Supplementary Figures




**Figure S1: Import rate of essential amino acids as a function of the MLE protein synthesis rate.**


a-h) Each square symbol represents a cell line from the NCI60 panel and the red solid line represents the expected ratio as determined from the relative amino acid abundance.



**Figure S2: Validation of the MLE protein synthesis rates.** a-d) [4,5-<sup>3</sup>H]-leucine incorporation into protein as a function of time for four selected cell lines. The red lines are linear fits to the data points. e) The MLE protein synthesis rate as a function of the [4,5-<sup>3</sup>H]-leucine incorporation rate into protein. Each data point represents a cancer cell line and the solid line represents a linear fit intercepting the origin.



**Figure S3: Protein synthesis rate per cell as a function of the proliferation rate.** Each square symbol represents a cell line from the NCI60 panel and the dashed red line is a linear fit to the data points.



**Figure S4: Correlation of measured and estimated protein contents.** a) Scatter plot of the model predicted protein synthesis rate vs the MLE protein synthesis rate. b) Scatter plot of the model predicted protein content vs the measured protein content. Each point represents a cell line and the diagonal line represents the case when both values are equal. Although they are not visible due to their small size, there are vertical error bars representing the 90% confidence interval due to variations in the model kinetic parameters. The horizontal error bars in panel b) represent the standard deviation of the protein content measurements.

## Supplementary Tables

Amino acid	$S_a$ (mol/mol)
histidine	0.021
isoleucine	0.048
leucine	0.083
lysine	0.084
methionine	0.020
phenylalanine	0.032
threonine	0.057
tryptophan	0.006
valine	0.061
alanine	0.088
arginine	0.055
asparagine	0.042
aspartate	0.053
cysteine	0.021
glutamate	0.057
glutamine	0.047
glycine	0.079
proline	0.046
serine	0.063
tyrosine	0.027

**Table S1:** Relative abundance of essential and non-essential amino acids in the expressed proteome [9, 21].



**Table S2: Genes whose expression correlates with cell volume.** The list of Affymetrix HG-U133 Plus 2.0 array probes whose expression values were highly correlated with the cell volumes ( $PCC > 0.5$ ) or highly negatively correlated with the cell volume ( $PCC < -0.5$ ) in the NCI60 cell lines.

Positively correlated				Negatively correlated			
Probe	Gene	<i>PCC</i>	<i>p</i>	Probe	Gene	<i>PCC</i>	<i>p</i>
200757 s at	CALU	0.65	0.00E+00	200773 x at	PTMA	-0.68	0.00E+00
200756 x at	CALU	0.63	0.00E+00	219067 s at	NSMCE4A	-0.66	0.00E+00
201828 x at	FAM127A	0.61	0.00E+00	216515 x at	PTMA	-0.66	1.00E-06
200755 s at	CALU	0.60	0.00E+00	202521 at	CTCF	-0.63	0.00E+00
214845 s at	CALU	0.60	0.00E+00	209753 s at	TMPO	-0.62	0.00E+00
202733 at	P4HA2	0.60	0.00E+00	208549 x at	LOC441454	-0.61	0.00E+00
200665 s at	SPARC	0.59	0.00E+00	224944 at	TMPO	-0.61	1.00E-06
209578 s at	POFUT2	0.59	0.00E+00	211376 s at	NSMCE4A	-0.60	0.00E+00
225303 at	KIRREL	0.59	0.00E+00	203388 at	ARRB2	-0.60	1.00E-06
212509 s at	MXRA7	0.59	0.00E+00	209754 s at	TMPO	-0.59	4.00E-06
206050 s at	RNH1	0.58	3.00E-06	201038 s at	ANP32A	-0.59	0.00E+00
213455 at	FAM114A1	0.58	3.00E-06	203276 at	LMNB1	-0.59	1.00E-05
226697 at	FAM114A1	0.58	0.00E+00	218911 at	YEATS4	-0.57	5.00E-06
202133 at	WWTR1	0.57	0.00E+00	212316 at	NUP210	-0.57	3.00E-06
201885 s at	CYB5R3	0.57	0.00E+00	231810 at	BRI3BP	-0.57	1.00E-06
225331 at	CCDC50	0.57	0.00E+00	211921 x at	PTMA	-0.57	0.00E+00
225803 at	FBXO32	0.57	9.00E-06	241968 at	-	-0.56	0.00E+00
210757 x at	DAB2	0.57	4.00E-06	200772 x at	PTMA	-0.56	0.00E+00
201172 x at	ATP6V0E1	0.57	2.00E-06	210053 at	TAF5	-0.56	1.00E-06
212119 at	RHOQ	0.57	0.00E+00	212479 s at	RMND5A	-0.56	1.10E-05
200096 s at	ATP6V0E1	0.57	0.00E+00	213947 s at	NUP210	-0.55	2.00E-06
203827 at	WIPI1	0.56	3.00E-06	203209 at	RFC5	-0.55	6.00E-06
200885 at	RHOC	0.56	4.00E-06	224753 at	CDCA5	-0.55	1.30E-05
203167 at	TIMP2	0.56	1.00E-06	203856 at	VRK1	-0.55	9.00E-06
201279 s at	DAB2	0.56	5.00E-06	202503 s at	KIAA0101	-0.54	2.00E-06
200787 s at	PEA15	0.56	0.00E+00	202387 at	BAG1	-0.54	6.00E-06
212120 at	RHOQ	0.56	0.00E+00	222264 at	HNRNPUL2	-0.54	2.00E-06
219637 at	ARMC9	0.56	1.00E-06	203302 at	DCK	-0.54	6.00E-06
212658 at	LHFPL2	0.55	9.00E-06	223154 at	MRPL1	-0.54	2.00E-06
202555 s at	MYLK	0.55	0.00E+00	201969 at	NASP	-0.54	1.20E-05
212722 s at	JMJD6	0.55	1.40E-05	202107 s at	MCM2	-0.54	4.00E-06
227628 at	GPX8	0.55	0.00E+00	216384 x at	LOC643287	-0.53	9.00E-06
200788 s at	PEA15	0.55	0.00E+00	204026 s at	ZWINT	-0.53	4.00E-06
231579 s at	TIMP2	0.55	0.00E+00	228569 at	PAPOLA	-0.53	4.00E-06
228564 at	LOC375295	0.55	3.00E-06	223268 at	C11orf54	-0.53	0.00E+00
202134 s at	WWTR1	0.55	1.00E-06	224760 at	SP1	-0.53	3.00E-06
200782 at	ANXA5	0.55	0.00E+00	222103 at	ATF1	-0.53	3.00E-06
224823 at	MYLK	0.54	9.00E-06	200047 s at	YY1	-0.53	1.40E-05
211433 x at	KIAA1539	0.54	1.80E-05	200091 s at	RPS25	-0.53	3.00E-06
200663 at	CD63	0.54	5.00E-06	206687 s at	PTPN6	-0.53	7.00E-06
218618 s at	FNDC3B	0.54	6.00E-06	225716 at	-	-0.53	2.40E-05
231907 at	-	0.54	7.00E-06	215947 s at	FAM136A	-0.53	2.00E-05
201278 at	DAB2	0.54	2.00E-05	215136 s at	EXOSC8	-0.53	1.50E-05
209264 s at	TSPAN4	0.53	3.00E-06	212482 at	RMND5A	-0.53	5.00E-06
208684 at	COPA	0.53	1.70E-05	218448 at	C20orf11	-0.53	1.00E-06
224560 at	TIMP2	0.53	0.00E+00	213054 at	-	-0.53	5.00E-06
203262 s at	FAM50A	0.53	8.00E-06	235138 at	VPS35	-0.52	3.00E-06
200614 at	CLTC	0.53	8.00E-06	217956 s at	ENOPH1	-0.52	4.50E-05
225032 at	FNDC3B	0.53	6.00E-06	219188 s at	MACROD1	-0.52	4.10E-05
204140 at	TPST1	0.53	2.20E-05	227586 at	TMEM170A	-0.52	1.40E-05
201616 s at	CALD1	0.53	1.10E-05	209421 at	MSH2	-0.52	1.10E-05
200700 s at	KDEL2	0.53	1.00E-06	201930 at	MCM6	-0.52	3.40E-05
200770 s at	LAMC1	0.53	1.00E-06	208808 s at	HMGB2	-0.52	2.80E-05
219390 at	FKBP14	0.53	1.20E-05	202690 s at	SNRPD1	-0.52	7.00E-06
226801 s at	LOC646890	0.53	3.10E-05	201051 at	ANP32A	-0.52	1.10E-05
229017 s at	DSTYK	0.53	3.00E-05	222214 at	-	-0.52	2.00E-06

214150 x at	ATP6V0E1	0.52	2.20E-05		203633 at	CPT1A	-0.52	3.90E-05
212470 at	SPAG9	0.52	1.00E-06		204798 at	MYB	-0.51	0.00E+00
218717 s at	LEPREL1	0.52	1.90E-05		209323 at	PRKRIR	-0.51	3.00E-05
202052 s at	RAI14	0.52	7.00E-06		218458 at	GMCL1	-0.51	2.50E-05
200673 at	LAPTM4A	0.52	5.00E-06		202978 s at	CREBZF	-0.51	2.90E-05
217785 s at	YKT6	0.52	1.40E-05		208643 s at	XRCC5	-0.51	2.80E-05
203891 s at	DAPK3	0.52	2.30E-05		205393 s at	CHEK1	-0.51	5.60E-05
223625 at	FAM126A	0.52	3.10E-05		200041 s at	BAT1	-0.51	7.60E-05
201098 at	COPB2	0.52	2.60E-05		225887 at	C13orf23	-0.51	3.90E-05
212723 at	JMJD6	0.52	1.80E-05		211475 s at	BAG1	-0.50	4.20E-05
210762 s at	DLC1	0.52	1.40E-05		212138 at	PDS5A	-0.50	2.90E-05
204584 at	L1CAM	0.52	3.10E-05		201035 s at	HADH	-0.50	7.00E-06
229465 s at	PTPRS	0.52	3.10E-05		223711 s at	THYN1	-0.50	4.50E-05
200643 at	HDLBP	0.52	1.40E-05		213762 x at	RBMX	-0.50	5.00E-05
220990 s at	MIR21	0.52	2.00E-06		208935 s at	LGALS8	-0.50	1.30E-05
228776 at	GJC1	0.52	3.00E-06		200069 at	SART3	-0.50	3.20E-05
241763 s at	FBXO32	0.51	4.40E-05		224610 at	SNHG1	-0.50	5.50E-05
225368 at	HIPK2	0.51	3.00E-06					
215489 x at	HOMER3	0.51	0.00E+00					
224663 s at	CFL2	0.51	0.00E+00					
212077 at	CALD1	0.51	8.00E-06					
204017 at	KDELR3	0.51	5.00E-06					
227239 at	FAM126A	0.51	2.20E-05					
200827 at	PLOD1	0.51	1.50E-05					
230146 s at	FREQ	0.51	3.90E-05					
205717 x at	PCDHGA12	0.51	2.60E-05					
209946 at	VEGFC	0.51	5.10E-05					
215706 x at	ZYX	0.51	1.00E-06					
212667 at	SPARC	0.51	4.00E-05					
226893 at	-	0.51	3.10E-05					
200096 s at	ATP6V0E1	0.51	3.30E-05					
202087 s at	CTSL1	0.51	0.00E+00					
209263 x at	TSPAN4	0.51	2.30E-05					
201536 at	DUSP3	0.51	8.00E-06					
226939 at	CPEB2	0.51	3.20E-05					
213112 s at	SQSTM1	0.51	7.50E-05					
209079 x at	PCDHGA12	0.51	2.50E-05					
211059 s at	GOLGA2	0.51	3.10E-05					
208785 s at	MAP1LC3B	0.50	2.20E-05					
200983 x at	CD59	0.50	8.00E-06					
207765 s at	KIAA1539	0.50	5.80E-05					
224791 at	ASAP1	0.50	3.30E-05					
212090 at	GRINA	0.50	1.10E-05					
200661 at	CTSA	0.50	1.00E-05					
225116 at	HIPK2	0.50	1.60E-05					
208782 at	FSTL1	0.50	4.90E-05					

**Table S3: Correlation between the expression of proteins/phosphoproteins and the cell volume in the NCI60 cell lines.**

Positively correlated			Negatively correlated		
Protein / Phosphoprotein	PCC	p	Protein / Phosphoprotein	PCC	p
Vimentin 57kD	0.36	0.0017	Phosphorylation of Cofilin at S3	-0.22	0.0589
AKT serine/threonine protein kinase	0.32	0.0055	E-cadherin protein	-0.20	0.0621
Phosphorylation of 4EBP1 (EIF4EBP1 Eukaryotic translation initiation factor 4E binding protein 1) protein at T37 and T46	0.29	0.0228	cleaved PARP (D214)	-0.20	0.0709
Phosphorylation of A-RAF at S299	0.28	0.0148	Phosphorylation of VEGFR2 at Y951	-0.19	0.0785
Phosphorylation of ATF2 at T69 and/or T71	0.26	0.0246	Phosphorylation of FRS2 alpha at Y436	-0.15	0.1554
Phosphorylation of ERK1/2 at T202 and/or Y204	0.21	0.0506	Phosphorylation of EGFR at Y1068	-0.14	0.1504
Bub3	0.20	0.0654	ErbB2 (receptor protein-tyrosine kinase)	-0.11	0.2049
Phosphorylation of FAK at Y397	0.20	0.0655	Phosphorylation of BCR at Y177	-0.11	0.2047
Phosphorylation of Aurora A at T288, Aurora B at T232 and/or Aurora C at T198	0.20	0.0514	Phosphorylation of ZAP70 at Y319 &/or SYK at Y352	-0.10	0.2212
Phosphorylation of CREB at S133	0.20	0.0624	Phosphorylation of EGFR at Y845	-0.10	0.2261
Phosphorylation of PKC alpha at S657	0.19	0.0683	Phosphorylation of Acetyl CoA carboxylase at S79	-0.10	0.2333
Phosphorylation of Arrestin 1 at S412	0.19	0.0826	Insulin Receptor beta	-0.09	0.2417
Cyclin D1 protein	0.17	0.0940	COX2 (PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)) protein	-0.07	0.2920
Phosphorylation of PKC alpha/betaII at T638 and/or T641	0.17	0.0917	Phosphorylation of PDGFR beta at Y751	-0.07	0.2821
Phosphorylation of Progesterone Receptor at S190	0.17	0.0990	Phosphorylation of Src protein at Y416	-0.07	0.2870
Phosphorylation of ASK1 at S83	0.17	0.1719	cleaved Caspase 3 (D175)	-0.06	0.3042
BMI1 (oncogene, DNA binding)	0.16	0.1173	Phosphorylation of LCK at Y505	-0.06	0.3335
ErbB3 (receptor protein-tyrosine kinase)	0.15	0.1091	Phosphorylation of TYK2 at Y1054 &/or Y1055	-0.06	0.3106
Phosphorylation of MARCKS at S152 and/or S156	0.15	0.1250	Phosphorylation of Src protein at Y527	-0.05	0.3227
4EBP-1 (EIF4EBP1 Eukaryotic translation initiation factor 4E binding protein 1) protein	0.14	0.1408	Phosphorylation of GAB1 at Y627	-0.05	0.3326
HIF-1alpha (Hypoxia inducible factor, basic helix-loop-helix transcription factor)	0.14	0.1461	Phosphorylation of CrkL at Y207	-0.05	0.3404
PDGFRb (pdgf-b receptor, tyrosine kinase)	0.14	0.1427	cleaved Caspase 6 (D162)	-0.05	0.3435
Phosphorylation of PKC pan/betaII at S660	0.14	0.1369	Phosphorylation of SHIP1 at Y1020	-0.05	0.3223
Phosphorylation of AKT on Ser473	0.14	0.1496	Phosphorylation of SHC at Y317	-0.05	0.3372
Phosphorylation of Bcl-2 at T56	0.14	0.1522	Phosphorylation of STAT3 protein at T727	-0.04	0.3469
Phosphorylation of TSC2 (Tuberous sclerosis 2) protein at T1462	0.13	0.1494	cleaved Caspase 7 (D198)	-0.04	0.3238
Phosphorylation of eIF4G at S1108	0.13	0.1627	Phosphorylation of p38 (MAPK14 Mitogen-activated protein kinase 14) protein at T180/Y182	-0.04	0.3140
Phosphorylation of NFkB p65 at S536	0.13	0.1718	Phosphorylation of STAT6 (Signal transducer and activator of transcription 6) protein at Y641	-0.04	0.3404
Epidermal growth factor receptor	0.12	0.1893	PLK1, polo-like kinase 1	-0.04	0.3355
Phosphorylation of Histone H3 at S28	0.11	0.1996	Phosphorylation of VEGFR2 at Y996	-0.04	0.3375
Phosphorylation of Ask1 at Y284	0.11	0.2043	Phosphorylation of PLC gamma1 at Y783	-0.03	0.3640
SMAD 1/5/8 (S/S)	0.11	0.2098	Phosphorylation of SMAD2 at S465 &/or 467	-0.03	0.3503
Phosphorylation of ATP Cytrate Lyase at S454	0.11	0.2135	Phosphorylation of ErbB2 at Y1248	-0.03	0.3631
Bcl-2 (Apoptosis regulator)	0.10	0.2309	cleaved Lamin A (D230)	-0.03	0.3845
Phosphorylation of FKHR at T24 and/or FKHL1 at T32	0.10	0.2320	Phosphorylation of EGFR at Y1173	-0.03	0.3480
Phosphorylation of Adducin at S662	0.09	0.2550	Phosphorylation of c-Abl of Y245	-0.02	0.3742
Phosphorylation of RPS6 (Ribosomal protein S6) protein at S235 and S236	0.09	0.2543	Phosphorylation of MAPK8 (JNK, mitogen-activated protein kinase 8) protein at T183/Y185	-0.02	0.3715
Phosphorylation of 4EBP1 (EIF4EBP1 Eukaryotic translation initiation factor 4E binding protein 1) protein at T70	0.09	0.2655	Phosphorylation of Histone H3 at S10, mitosis maker	-0.02	0.3729
Phosphorylation of EGFR at Y1045	0.09	0.2657	Phosphorylation of PDGFR beta at Y716	-0.02	0.3744
PTEN protein-tyrosine phosphatase	0.09	0.2684	Phosphorylation of RET at Y905	-0.02	0.4118
Phosphorylation of EGFR at S1046 and/or S1047	0.09	0.2663	Phosphorylation of BAD (BCL2-associated agonist of cell death) protein at S112	-0.02	0.4311
Phosphorylation of eNOS-NOSIII at S116	0.08	0.2882	Phosphorylation of FAK at Y576 and/or 577	-0.02	0.3685
Phosphorylation of RPS6 (Ribosomal protein S6) protein at S240 and S244	0.08	0.2754	Phosphorylation of Raf at S259	-0.02	0.3866

Phosphorylation of EGFR at Y992	0.08	0.2875	Phosphorylation of SMAD2 at S245 &/or S250 &/or S255	-0.02	0.3825
signal transducer and activator of transcription 3 (acute-phase response factor)	0.08	0.2875	Smac/Diablo	-0.02	0.3914
Phosphorylation of CHK1 at S345	0.08	0.2773	CASP9, caspase 9, apoptosis-related cysteine protease	-0.01	0.3962
Phosphorylation of AMPK alpha1 at S485	0.08	0.2985	p38 (MAPK14 Mitogen-activated protein kinase 14) protein	-0.01	0.3962
Phosphorylation of c-Kit at Y703	0.08	0.2894	p70S6K (RPS6KB1 Ribosomal protein S6 kinase, 70kDa, polypeptide 1) protein	-0.01	0.4111
Phosphorylation of EGFR at Y1148	0.08	0.3155	Phosphorylation of PKC zeta-lambda at T410 and/or T403	-0.01	0.3913
Phosphorylation of p53 at S15	0.07	0.3052	Phosphorylation of MET at Y1234 and/or Y1235	-0.01	0.3890
Phosphorylation of AMPK beta1 at S108	0.07	0.3245	cyclin B1	-0.01	0.4391
Phosphorylation of PRAS40 at T246	0.07	0.3321	Phosphorylation of PAK1 at S199 and/or S204 and/or PAK2 at S192 and/or S197	-0.01	0.4037
Phosphorylation of 4EBP1 (EIF4EBP1 Eukaryotic translation initiation factor 4E binding protein 1) protein at S65	0.07	0.3290	Phosphorylation of PYK2 at Y402	-0.01	0.4515
Phosphorylation of FKHR at S256	0.07	0.3330	Phosphorylation of ALK at Y1586	-0.01	0.4550
Phosphorylation of T308 on AKT	0.07	0.3088	Phosphorylation of PKC theta at T538	-0.01	0.4044
ER (estrogen receptor) alpha protein	0.07	0.3014	cleaved Caspase 9 (D315)	-0.01	0.4031
Phosphorylation of mTOR (Mechanistic target of rapamycin (serine/threonine kinase)) protein at S2448	0.07	0.3453			
Phosphorylation of Ikb alpha at S32 and/or S36	0.06	0.3633			
Phosphorylation of c-Kit at Y719	0.06	0.3537			
Cyclin A (Cell cycle regulation)	0.06	0.3267			
Phosphorylation of CrkII at Y221	0.05	0.3595			
Phosphorylation of FADD at S194	0.05	0.3920			
Phosphorylation of ATF2 at T71	0.05	0.3677			
Phosphorylation of Estrogen Receptor alpha at S118	0.05	0.4112			
Phosphorylation of PDK1 (PDK1 3-phosphoinositide dependent protein kinase-1) protein at S241	0.05	0.4023			
Beclin1	0.05	0.3848			
Phosphorylation of p27 of T187	0.04	0.4362			
Phosphorylation of IRS1 at S612	0.04	0.4369			
Phosphorylation of SGK1 (Serum/glucocorticoid regulated kinase 1) protein at S78	0.04	0.4444			
Phosphorylation of B-Raf at S445	0.04	0.4044			
MEK 1/2 protein	0.04	0.4386			
Survivin	0.04	0.4370			
Phosphorylation of MEK1 and MEK2 proteins at S217/S221	0.04	0.4564			
Phosphorylation of PTEN at S380	0.04	0.4558			
Phosphorylation of Syk at Y525 &/or Y526	0.03	0.4711			
p53	0.03	0.4024			
Phosphorylation of RSK3 at T356 and/or S360	0.03	0.4580			
IRS1 (insulin receptor substrate 1) protein	0.03	0.4722			
Phosphorylation of C-RAF at S338	0.03	0.4839			
mTOR (Mechanistic target of rapamycin (serine/threonine kinase)) protein	0.03	0.4749			
Phosphorylation of eNOS at S113	0.03	0.4574			
Phosphorylation of BAD at S155	0.03	0.4776			
Phosphorylation of IGF-1 Receptor at Y1135/1136/Insulin Receptor (Y1150/1151)	0.03	0.4101			
Phosphorylation of PRK1 at T774 and/or PRK2 at T816	0.03	0.4680			
Phosphorylation of Chk2 at S33 and/or S35	0.03	0.4109			
Phosphorylation of BAD at S136	0.03	0.4715			
Phosphorylation of p70 S6 Kinase at S371	0.03	0.5001			
Phosphorylation of ErbB3 at Y1197	0.03	0.5001			
Phosphorylation of SHP2 at Y580	0.03	0.5081			
Phosphorylation of Bcl-2 at S70	0.03	0.5007			
CREB protein	0.02	0.5019			
Phosphorylation of RAS-GFR1 at S916	0.02	0.5036			
Bad (BCL2-antagonist of cell death)	0.02	0.4822			
Phosphorylation of SEK1-MKK4 at S80	0.02	0.5118			
Phosphorylation of PKC delta at T505	0.02	0.5229			
Phosphorylation of p90RSK at S380	0.02	0.4965			
Bax (BCL2-associated X protein)	0.02	0.5022			

Phosphorylation of eNOS at S1177	0.02	0.4352			
X-IAP (x-linked inhibitor of apoptosis)	0.02	0.5139			
Phosphorylation of IGF1 Receptor at Y1131 and/or Insulin Receptor at Y1146	0.02	0.5183			
Phosphorylation of LKB1 at S334	0.02	0.5210			
Phosphorylation of STAT3 protein at Y705	0.02	0.4512			
Phosphorylation of p40 phox at T154	0.02	0.4772			
Phosphorylation of c-Abl of T735	0.02	0.5289			
Phosphorylation of mTOR at S2481	0.02	0.5280			
Phosphorylation of VEGFR2 at Y1175	0.02	0.5296			
Phosphorylation of PAK1 at T423 and/or PAK2 at T402	0.02	0.5498			
Phosphorylation of Mst1 at T183 and/or Mst 2 at T180	0.02	0.5401			
Phosphorylation of MSK1 at S360	0.01	0.5391			
Phosphorylation of ErbB3 at Y1289	0.01	0.5420			
Bak (BCL2-antagonist/killer 1)	0.01	0.5019			
Phosphorylation of PLK1 at T210	0.01	0.5580			
Phosphorylation of Jak2 at Y1007 and/or Y1008	0.01	0.5496			
Phosphorylation of ACK1 at Y857 and/or Y858	0.01	0.5495			
Phosphorylation of TUBERIN TSC2 at Y1571	0.01	0.5516			
ErbB4 (receptor protein-tyrosine kinase)	0.01	0.5462			
Phosphorylation of FKHL1 at S253	0.01	0.5613			
Phosphorylation of beta Catenin at T41 and/or S45	0.01	0.5414			
Phosphorylation of p70 S6 Kinase at T412	0.01	0.5469			
Phosphorylation of cPLA2 at S505	0.01	0.5530			
Phosphorylation of PKA C at T197	0.01	0.5570			
Phosphorylation of LKB1 (STK11 serine/threonine kinase 11) protein at S428	0.01	0.5597			
Phosphorylation of Ezrin at T156, Radixin at T564, and/or Moesin at T558	0.01	0.5664			
Phosphorylation of STAT2 at Y690	0.01	0.5411			
Phosphorylation of p70S6K (RPS6KB1 Ribosomal protein S6 kinase, 70kDa, polypeptide 1) protein at T389	0.01	0.5607			
Phosphorylation of Paxillin at Y118	0.00	0.5514			
Phosphorylation of Elk1 at S383	0.00	0.5751			
cleaved Caspase 9 (D330)	0.00	0.5631			
Phosphorylation of GSK3 alpha at Y279 and/or GSK3 beta at Y216	0.00	0.5722			
Phosphorylation of eIF4E at S209	0.00	0.4562			
Phosphorylation of JAK1 at Y1022 and/or Y1023	0.00	0.4194			
KIT (receptor for stem cell factor, tyrosine kinase)	0.00	0.5002			
Phosphorylation of GSK3 alpha/beta at S21and or S9	0.00	0.4331			
ERK 1/2 protein	0.00	0.4224			
Phosphorylation of STAT5 protein at Y694	0.00	0.4802			
Phosphorylation of STAT1 at Y701	0.00	0.4367			
Bcl-x1 (BCL2-like 1)	0.00	0.4249			
Phosphorylation of VAV3 at Y173	0.00	0.4066			

**Table S4: FDA approved drugs included in the *in vitro* growth inhibition analysis.** NSC stands for National Service Center and it is the identifier utilized by the Department of Therapeutics Program at the National Cancer Institute [22].

NSC	Mechanism of Action	Name
177023	Alkaline Phosphatase Inhibitor	Levamisole
13875	Alkylating Agents	Altretamine
409962	Alkylating Agents	BCNU
125066	Alkylating Agents	Bleomycin
750	Alkylating Agents	Busulfan
241240	Alkylating Agents	Carboplatin
3088	Alkylating Agents	Chlorambucil
119875	Alkylating Agents	Cisplatin
26271	Alkylating Agents	Cyclophosphamide
45388	Alkylating Agents	Dacarbazine
109724	Alkylating Agents	Ifosfamide
79037	Alkylating Agents	Lomustine
8806	Alkylating Agents	Melphalan
26980	Alkylating Agents	Mitomycin C
762	Alkylating Agents	Nitrogen mustard
266046	Alkylating Agents	Oxaliplatin
25154	Alkylating Agents	Pipobroman
6396	Alkylating Agents	Thiotepa
9706	Alkylating Agents	Tretamin
34462	Alkylating Agents	Uracil mustard
628503	Antimitotic Agents	Docetaxel
608210	Antimitotic Agents	Navelbine
125973	Antimitotic Agents	Taxol
49842	Antimitotic Agents	Vinblastine
67574	Antimitotic Agents	Vincristine
719344	Aromatase Inhibitor	Anastrozole
713563	Aromatase Inhibitor	Exemestane
719345	Aromatase Inhibitor	Letrozole
23759	Aromatase Inhibitor	Testolactone
719627	COX-2 Inhibitor	Celebrex
27640	DNA Antimetabolites	5-Fluorouracil deoxyriboside
63878	DNA Antimetabolites	Ara-C
287459	DNA Antimetabolites	Cytarabine
127716	DNA Antimetabolites	Decitabine
312887	DNA Antimetabolites	Fludarabine phosphate
613327	DNA Antimetabolites	Gemcitabine
32065	DNA Antimetabolites	Hydroxyurea
218321	DNA Antimetabolites	Pentostatin
752	DNA Antimetabolites	Thioguanine
755	DNA Antimetabolites	Thiopurine
71423	Estrogen analog	Ethinyl Estradiol
719276	Estrogen Receptor Antagonist	Fulvestrant
180973	Estrogen Receptor Antagonist	Tamoxifen
226080	mTOR inhibitor	Rapamycin
683864	mTOR inhibitors	Temsirolimus
733504	mTOR inhibitors	Everolimus
105014	DNA Antimetabolites	Cladribine
686673	NA	2-Amino-6-methoxypurine arabinoside
713563	NA	6-Methylenandrosta-1,4-diene-3,17-dione
14229	NA	Acrichine
369100	NA	Aldara
246131	NA	Antibiotic AD 32
92859	NA	Arsenic Oxide, As <sub>2</sub> O <sub>3</sub>
706363	NA	Arsenic Trioxide

1390	NA	Bleminol
3590	NA	Calcium folinate
88536	NA	Calusterone
38721	NA	Chloditan
702294	NA	Estramustine sodium phosphate
296961	NA	Ethiofos
12198	NA	Masterone/Econazole
45923	NA	Meladinine
279836	Topoisomerase II Inhibitors	Mitoxantrone
23162	NA	Nandrolin
77213	NA	Natunalar
18509	NA	Pentanoic acid, 5-amino-4-oxo-, hydrochloride
256942	NA	Pidorubicin hydrochloride
122758	NA	Retinoic acid
701852	NA	SAHA
362856	NA	Temozolomide
113891	NA	Uromitexan
66847	NA	Yodomin
85998	O-GlcNAc Inhibitor	Streptozocin
681239	Proteasome Inhibitor	Bortezomib
698037	RNA/DNA Antimetabolites	Pemetrexed
102816	RNA/DNA Antimetabolites	Azacytidine
712807	RNA/DNA Antimetabolites	Capecitabine
606869	RNA/DNA Antimetabolites	Clofarabine
19893	RNA/DNA Antimetabolites	Fluorouracil
740	RNA/DNA Antimetabolites	Methotrexate
82151	Topoisomerase II Inhibitors	Daunorubicin
123127	Topoisomerase II Inhibitors	Doxorubicin
141540	Topoisomerase II Inhibitors	Etoposide
169780	Topoisomerase II Inhibitors	ICRF-187
256439	Topoisomerase II Inhibitors	Idarubicin
122819	Topoisomerase II Inhibitors	Teniposide
616348	Topoisomerase I Inhibitors	Irinotecan
609699	Topoisomerase I Inhibitors	Topotecan
3053	Transcription/DNA synthesis Inhibitor	Actinomycin D
24559	Transcription/DNA synthesis Inhibitor	Mithramycin
697979	Translation Inhibitor	Ontak
732517	Tyrosine Kinase Inhibitor	Dasatinib
718781	Tyrosine Kinase Inhibitor	Erlotinib
715055	Tyrosine Kinase Inhibitor	Gefitinib
688097	Tyrosine Kinase Inhibitor	Herceptin
743414	Tyrosine Kinase Inhibitor	Imatinib
632307	Tyrosine Kinase Inhibitor	Lapatinib
747599	Tyrosine Kinase Inhibitor	Nilotinib
747971	Tyrosine Kinase Inhibitor	Sorafenib
750690	Tyrosine Kinase Inhibitor	Sunitinib
633782	Sterol Synthesis Inhibitor	Simvastatin
633781	Sterol Synthesis Inhibitor	Lovastatin
281245	Sterol Synthesis Inhibitor	Mevastatin

Cell line	Protein synthesis rate (fmol/hour/cell)	Protein content (ng/cell)
BR:BT-549	89	0.262
BR:HS578T	128	0.295
BR:MCF7	70	0.185
BR:MDA-MB-231	47	0.241
BR:T-47D	52	0.253
CNS:SF-268	55	0.308
CNS:SF-295	285	0.411
CNS:SF-539	90	0.394
CNS:SNB-19	111	0.326
CNS:SNB-75	77	0.786
CNS:U251	78	0.361
CO:COLO205	64	0.257
CO:HCC-2998	125	0.279
CO:HCT-116	114	0.202
CO:HCT-15	69	0.179
CO:HT29	99	0.250
CO:KM12	35	0.198
CO:SW-620	61	0.132
LC:A549/ATCC	74	0.244
LC:EKVX	55	0.413
LC:HOP-62	73	0.389
LC:HOP-92	128	0.560
LC:NCI-H226	65	0.550
LC:NCI-H23	50	0.378
LC:NCI-H322M	73	0.221
LC:NCI-H460	57	0.322
LC:NCI-H522	67	0.465
LE:CCRF-CEM	43	0.076
LE:HL-60	62	0.162
LE:K-562	133	0.231
LE:MOLT-4	33	0.101
LE:RPMI-8226	139	0.167
LE:SR	45	0.021
ME:LOXIMVI	124	0.283
ME:M14	82	0.259
ME:MALME-3M	61	0.319
ME:MDA-MB-435	90	0.211
ME:MDA-N	NA	NA
ME:SK-MEL-2	143	0.301
ME:SK-MEL-28	181	0.345
ME:SK-MEL-5	191	0.294
ME:UACC-257	49	0.254
ME:UACC-62	107	0.664
OV:IGROV1	124	0.308
OV:OVCAR-3	60	0.257
OV:OVCAR-4	65	0.441
OV:OVCAR-5	35	0.230
OV:OVCAR-8	34	0.234
OV:OVCAR-8/ADR	51	0.285
OV:SK-OV-3	56	0.257
PR:DU-145	58	0.390
PR:PC-3	154	0.606
RE:786-0	79	0.372
RE:A498	97	0.426
RE:ACHN	155	0.279
RE:CAKI-1	101	0.555
RE:RXF-393	117	0.581
RE:SN12C	62	0.214
RE:TK-10	46	0.373
RE:UO-31	46	0.215

**Table S5:** MLE protein synthesis rates and measured protein content for each NCI60 cell line.



Amino acid	$\sigma_a$ (fmol/cell/hour)
isoleucine	2.0
leucine	2.1
lysine	2.5
methionine	2.6
phenylalanine	2.6
threonine	2.8
tryptophan	2.9
valine	2.9

**Table S6:** Maximum likelihood estimate of the variances ( $\sigma_a$ ). The value for histidine is not shown because its exchange fluxes were not reported.